Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

Rhea-AI Summary

Apogee Therapeutics (NASDAQ: APGE) will report Part A 52-week results from the Phase 2 APEX trial of zumilokibart (APG777) on Monday, March 23, 2026. Following the announcement, the company will host a conference call and live webcast at 8:00 a.m. ET.

According to the company, the live webcast will be accessible via the Investors section on the company website and a replay will be available after the call.

News Market Reaction – APGE

+19.99%

5 alerts

+19.99% Session close to close

+30.3% Peak in 2 hr 5 min

$4.59B Market Cap

0.0x Rel. Volume

In the Mar 23 session, APGE gained 19.99%, reflecting a significant positive market reaction. Argus tracked a peak move of +30.3% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +20.0% in the session following this news. A strong positive reaction aligns with p...

Analysis

The stock surged +20.0% in the session following this news. A strong positive reaction aligns with prior focus on APG777 as a lead asset, but historical conference/clinical‑trial announcements averaged a -8.74% move, including a -17.32% drop around earlier APEX Part A communication. Sustained gains would need support from the actual 52‑week APEX data. Elevated volume at 2.63x average and relatively high short positioning could have amplified any upside once results were communicated.

Key Figures

APEX Part A duration: 52-week data Trial phase: Phase 2 Conference call time: 8:00 a.m. ET +5 more

8 metrics

APEX Part A duration 52-week data Phase 2 APEX trial in moderate-to-severe atopic dermatitis

Trial phase Phase 2 APEX trial of zumilokibart (APG777)

Conference call time 8:00 a.m. ET Webcast on March 23, 2026

Conference call date March 23, 2026 Reporting Part A 52-week APEX data

Current share price $66.04 Prior to March 22, 2026 announcement

Price change 24h -3.59% Trading before data call announcement

52-week range $26.20–$84.56 Shares 21.9% below 52-week high

Volume multiple 2.63x Today’s volume vs 20-day average

Previous Conferences,clinical trial Reports

2 past events · Latest: Jul 06 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 06	APEX Part A call	Neutral	-17.3%	Announcement of July 2025 call for APEX Part A 16-week atopic dermatitis data.
Feb 28	APG990 interim call	Neutral	-0.2%	Scheduled March 2025 call on APG990 healthy volunteer data and APG777 combo strategy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Similar conference/clinical-trial call announcements have previously coincided with negative reactions, with an average move of -8.74% on these tags.

Recent Company History

Over the past year, Apogee’s tagged conferences/clinical trial announcements have focused on early and mid‑stage data updates for APG777 and APG990. A July 2025 call previewing APEX Part A 16‑week data in atopic dermatitis preceded a -17.32% move, while a February 2025 call for APG990 interim results and APG777 combination plans saw a modest -0.16% reaction. Today’s scheduled Part A 52‑week APEX readout continues this pattern of data‑driven event communication.

Key Terms

phase 2, atopic dermatitis, biologics, clinical-stage biotechnology

4 terms

phase 2 medical

"report Part A 52-week data from the Phase 2 APEX trial of zumilokibart"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

atopic dermatitis medical

"APEX trial of zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

biologics medical

"advancing optimized, novel biologics with potential for best-in-class profiles"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

clinical-stage biotechnology medical

"a clinical-stage biotechnology company advancing optimized, novel biologics"

Clinical-stage biotechnology refers to biotechnology companies that are in the process of testing new medical treatments or drugs in human trials. This stage is crucial because it indicates that these treatments have shown enough promise in earlier research to be evaluated for safety and effectiveness in people. For investors, it signals a key phase where potential breakthroughs are being tested, but also involves higher risk since the outcomes are still uncertain.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Webcast to be held Monday, March 23rd at 8:00 a.m. ET

SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

Webcast Details
Apogee Therapeutics’ live webcast of the Phase 2 APEX Part A results will begin on Monday, March 23^rd at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company’s website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.

About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.

Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
Noel.Kurdi@apogeetherapeutics.com

Media Contact:
Dan Budwick
1AB Media
dan@1abmedia.com

FAQ

When will Apogee Therapeutics (APGE) present the Part A 52-week APEX data?

Apogee will present Part A 52-week APEX data on March 23, 2026 during a scheduled webcast and call. According to the company, the presentation begins at 8:00 a.m. ET and will include discussion of Phase 2 results for zumilokibart (APG777).

How can investors access Apogee Therapeutics (APGE) March 23, 2026 webcast?

Investors can access the live webcast via the company's Investor website or the provided event link. According to the company, the webcast begins at 8:00 a.m. ET and a replay will be posted after the call for later viewing.

What data will Apogee Therapeutics (APGE) discuss on the March 23, 2026 call?

The company will discuss Part A 52-week data from the Phase 2 APEX trial of zumilokibart (APG777) in moderate-to-severe atopic dermatitis. According to the company, the call will review safety and efficacy results from the 52-week readout.

Will a replay of the Apogee (APGE) March 23, 2026 webcast be available?

Yes, a replay will be available after the live event for on-demand viewing. According to the company, the replay will be posted in the Investors section of the company website following the March 23, 2026 webcast.

What time is Apogee Therapeutics (APGE) hosting the conference call on March 23, 2026?

The conference call and webcast are scheduled for 8:00 a.m. ET on March 23, 2026. According to the company, the live event will present Part A 52-week Phase 2 APEX results for zumilokibart (APG777).